ExpreS2ion Biotech Holding SEK 53m Capital Raise | Q1 2026

About ExpreS2ion Biotech Holding AB 

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. The company wants to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. 

ExpreS2ion’s lead clinical program is ES2B-C001, a therapeutic cancer vaccine aimed at cancers overexpressing the HER2 receptor. A clinical phase I trial in metastatic breast cancer has started in three clinical sites in Austria. On February 3rd, 2026, ExpreS2ion announced that five out of six evaluable patients demonstrated a drug-specific immune response following treatment with ES2B-C001. The Company also reported that patient enrolment and screening continue to progress as planned, and that additional patients are available to proceed once dosing is permitted following the required safety reviews. Based on current visibility, ExpreS2ion remains on track to complete the dose-escalation portion of the study around mid-2026 and the expansion portion toward the end of 2026, subject to ongoing recruitment, safety reviews, and overall study conduct progressing as expected. 

The net proceed from the Share Issue is intended to be used as follows: 

• Advance ES2B-C001. Complete Phase I (Ia and Ib) through safety and maximum tolerated dose readout, with potential immunogenicity and early efficacy signals, representing a key value inflection point, and support business development activities to pursue partnering or outlicensing opportunities. 
• Strengthen shared R&D and manufacturing capabilities. Investment in internal development, CMC-compatibility, and platform capabilities that de-risk execution, improve manufacturability, and compound across programs. 
• Grow the contract research business. Increase service revenues and margins, and validate the platform with external customers. 
• Co-finance grant projects. Limited co-financing of externally funded projects with future pipeline/licensing opportunities. 

Press release 

Website: https://expres2ionbio.com/